Federal Register / Vol. 80, No. 53 / Thursday, March 19, 2015 / Notices 14391 

Dated: March 13, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06270 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Advisory Committee on Research on 

Women’s Health. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Advisory Committee 

on Research on Women’s Health. 

Date: April 10, 2014. 

Time: 9:00 a.m. to 4:00 p.m. 

Agenda: The Committee serves to advise 

and make recommendations to the Director, 

Office of Research on Women’s Health 

(ORWH) on a broad range of topics including, 

the current scope of research on women’s 

health and the influence of sex and gender 

on human health, efforts to understand the 

issues related to women in biomedical 

careers and their needs, and the current 

status of inclusion of women in clinical trials 

research. 

Place: National Institutes of Health, 

Building 35, Room 620/630, 35 Convent 

Drive, Bethesda, MD 20892. 

Contact Person: Susan E Maier, Ph.D., NIH/ 

OD, 6707 Democracy Blvd., Room 400, 

Bethesda, MD 20852, 301–435–1573, 

maiers@mail.nih.gov. 

Any interested person may file written 

comments for the public record by 

submitting their comments to the following 

email address ACRWHComments@

sp10mail.nih.gov. Written comments for the 

public record must not exceed two singlespaced, typed pages, using a 12-point 

typeface and 1 inch margins; it is preferred 

that the document be prepared in the MS 

Word® format. Only testimony submitted to 

this Web site and received in advance of the 

meeting are part of the official meeting 

record. 

Supplementary Information: A draft 

agenda for this meeting is posted at 

http://orwh.od.nih.gov/about/acrwh/

index.asp. The meeting will be live-video 

streamed at http://videocast.nih.gov/. 

Individuals who plan to attend the meeting 

in person should contact Faith Zeff at 

faith.zeff@nih.gov. Members of the media 

will also need to register. In the interest of 

security, NIH has instituted stringent 

procedures for entrance onto the NIH 

campus. All visitor vehicles, including 

taxicabs, hotel, and airport shuttles will be 

inspected before being allowed on campus. 

Visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: March 13, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06267 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program; List of Petitions Received 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Health Resources and 

Services Administration (HRSA) is 

publishing this notice of petitions 

received under the National Vaccine 

Injury Compensation Program (the 

Program), as required by Section 

2112(b)(2) of the Public Health Service 

(PHS) Act, as amended. While the 

Secretary of Health and Human Services 

is named as the respondent in all 

proceedings brought by the filing of 

petitions for compensation under the 

Program, the United States Court of 

Federal Claims is charged by statute 

with responsibility for considering and 

acting upon the petitions. 

FOR FURTHER INFORMATION CONTACT: For 

information about requirements for 

filing petitions, and the Program in 

general, contact the Clerk, United States 

Court of Federal Claims, 717 Madison 

Place NW., Washington, DC 20005, 

(202) 357–6400. For information on 

HRSA’s role in the Program, contact the 

Director, National Vaccine Injury 

Compensation Program, 5600 Fishers 

Lane, Room 11C–26, Rockville, MD 

20857; (301) 443–6593. 

SUPPLEMENTARY INFORMATION: The 

Program provides a system of no-fault 

compensation for certain individuals 

who have been injured by specified 

childhood vaccines. Subtitle 2 of Title 

XXI of the PHS Act, 42 U.S.C. 300aa-10 

et seq., provides that those seeking 

compensation are to file a petition with 

the U.S. Court of Federal Claims and to 

serve a copy of the petition on the 

Secretary of Health and Human 

Services, who is named as the 

respondent in each proceeding. The 

Secretary has delegated this 

responsibility under the Program to 

HRSA. The Court is directed by statute 

to appoint special masters who take 

evidence, conduct hearings as 

appropriate, and make initial decisions 

as to eligibility for, and amount of, 

compensation. 

A petition may be filed with respect 

to injuries, disabilities, illnesses, 

conditions, and deaths resulting from 

vaccines described in the Vaccine Injury 

Table (the Table) set forth at Section 

2114 of the PHS Act or as set forth at 

42 CFR 100.3, as applicable. This Table 

lists for each covered childhood vaccine 

the conditions that may lead to 

compensation and, for each condition, 

the time period for occurrence of the 

first symptom or manifestation of onset 

or of significant aggravation after 

vaccine administration. Compensation 

may also be awarded for conditions not 

listed in the Table and for conditions 

that are manifested outside the time 

periods specified in the Table, but only 

if the petitioner shows that the 

condition was caused by one of the 

listed vaccines. 

Section 2112(b)(2) of the PHS Act, 42 

U.S.C. 300aa-12(b)(2), requires that 

‘‘[w]ithin 30 days after the Secretary 

receives service of any petition filed 

under section 2111 the Secretary shall 

publish notice of such petition in the 

Federal Register.’’ Set forth below is a 

list of petitions received by HRSA on 

February 1, 2015, through February 28, 

2015. This list provides the name of 

petitioner, city and state of vaccination 

(if unknown then city and state of 

person or attorney filing claim), and 

case number. In cases where the Court 

has redacted the name of a petitioner 

and/or the case number, the list reflects 

such redaction. 

Section 2112(b)(2) also provides that 

the special master ‘‘shall afford all 

interested persons an opportunity to 

submit relevant, written information’’ 

relating to the following: 

1. The existence of evidence ‘‘that 

there is not a preponderance of the 


Rmajette on DSK2VPTVN1PROD with NOTICES